Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based specialty pharmaceutical company Durect has revealed that Voyager Pharmaceutical has observed positive outcome trends among women, but not men in a truncated phase III clinical trial for Alzheimer's treatment Memryte.
Subscribe to our email newsletter
US-based Voyager terminated the trial of Memryte, an investigational drug for the treatment of Alzheimer’s disease, in October 2006. The pharmaceutical company’s pipeline Alzheimer’s disease treatment uses Durect’s sustained-release technology.
According to Durect, Voyager now intends to work on developing Memryte for the treatment of Alzheimer’s disease in women and on seeking a potential partner for the program.
Durect said that it has not independently verified the analysis performed or conclusions made by Voyger during the company’s late-stage trials of Memryte.